

Jianjun Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/319830/publications.pdf>

Version: 2024-02-01

71
papers

3,311
citations

159585

30
h-index

149698

56
g-index

71
all docs

71
docs citations

71
times ranked

4321
citing authors

#	ARTICLE	IF	CITATIONS
1	An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site. <i>Pharmaceutical Research</i> , 2012, 29, 2943-2971.	3.5	610
2	Advances in redox-responsive drug delivery systems of tumor microenvironment. <i>Journal of Nanobiotechnology</i> , 2018, 16, 74.	9.1	264
3	Discovery of 4-Substituted Methoxybenzoyl-aryl-thiazole as Novel Anticancer Agents: Synthesis, Biological Evaluation, and Structure-Activity Relationships. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 1701-1711.	6.4	162
4	Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site. <i>European Journal of Medicinal Chemistry</i> , 2018, 151, 482-494.	5.5	162
5	Discovery of Novel 2-Aryl-4-benzoyl-imidazoles Targeting the Colchicines Binding Site in Tubulin As Potential Anticancer Agents. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 7414-7427.	6.4	111
6	Discovery of Novel 2-Aryl-4-benzoyl-imidazole (ABI-III) Analogues Targeting Tubulin Polymerization As Antiproliferative Agents. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 7285-7289.	6.4	100
7	Advances of blood cell-based drug delivery systems. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 96, 115-128.	4.0	95
8	Design, Synthesis, and Biological Evaluation of Stable Colchicine Binding Site Tubulin Inhibitors as Potential Anticancer Agents. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 7355-7366.	6.4	83
9	Recent advances in small molecule based cancer immunotherapy. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 582-598.	5.5	74
10	Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agents. <i>European Journal of Medicinal Chemistry</i> , 2019, 179, 537-546.	5.5	73
11	Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 4782-4795.	3.0	64
12	Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment. <i>European Journal of Medicinal Chemistry</i> , 2020, 208, 112831.	5.5	64
13	Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1. <i>European Journal of Medicinal Chemistry</i> , 2020, 199, 112377.	5.5	63
14	Photo-conversion of two epimers (20R and 20S) of pregna-5,7-diene-3 β , 17 α , 20-triol and their bioactivity in melanoma cells. <i>Steroids</i> , 2009, 74, 218-228.	1.8	60
15	Novel vitamin D photoproducts and their precursors in the skin. <i>Dermato-Endocrinology</i> , 2013, 5, 7-19.	1.8	56
16	Discovery of Novel Benzimidazole and Indazole Analogues as Tubulin Polymerization Inhibitors with Potent Anticancer Activities. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 4498-4515.	6.4	56
17	Light-Activatable Prodrug and AIEgen Copolymer Nanoparticle for Dual-Drug Monitoring and Combination Therapy. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 18691-18700.	8.0	54
18	A comprehensive review of cytochrome P450 2E1 for xenobiotic metabolism. <i>Drug Metabolism Reviews</i> , 2019, 51, 178-195.	3.6	53

#	ARTICLE	IF	CITATIONS
19	Novel Tubulin Polymerization Inhibitors Overcome Multidrug Resistance and Reduce Melanoma Lung Metastasis. <i>Pharmaceutical Research</i> , 2012, 29, 3040-3052.	3.5	50
20	Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 8338-8358.	6.4	50
21	Nanotechnology in retinal drug delivery. <i>International Journal of Ophthalmology</i> , 2018, 11, 1038-1044.	1.1	48
22	Synergistic Chemotherapy for Breast Cancer and Breast Cancer Brain Metastases via Paclitaxel-Loaded Oleonic Acid Nanoparticles. <i>Molecular Pharmaceutics</i> , 2020, 17, 1343-1351.	4.6	47
23	Synthesis and antiproliferative activity of imidazole and imidazoline analogs for melanoma. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 3183-3187.	2.2	46
24	Vitamin D and its analogs as anticancer and anti-inflammatory agents. <i>European Journal of Medicinal Chemistry</i> , 2020, 207, 112738.	5.5	45
25	Recent advances in DDR (DNA damage response) inhibitors for cancer therapy. <i>European Journal of Medicinal Chemistry</i> , 2022, 230, 114109.	5.5	45
26	Synthesis of phospholipase A2 inhibitory biflavonoids. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 2373-2375.	2.2	42
27	Near-Infrared II Light-Triggered Robust Carbon Radical Generation for Combined Photothermal and Thermodynamic Therapy of Hypoxic Tumors. <i>Advanced Functional Materials</i> , 2021, 31, 2101709.	14.9	42
28	Discovery of novel cell-penetrating and tumor-targeting peptide-drug conjugate (PDC) for programmable delivery of paclitaxel and cancer treatment. <i>European Journal of Medicinal Chemistry</i> , 2021, 213, 113050.	5.5	38
29	Lumisterol is metabolized by CYP11A1: Discovery of a new pathway. <i>International Journal of Biochemistry and Cell Biology</i> , 2014, 55, 24-34.	2.8	37
30	Design, synthesis, and bioevaluation of pyrazolo[1,5-a]pyrimidine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site with potent anticancer activities. <i>European Journal of Medicinal Chemistry</i> , 2020, 202, 112519.	5.5	36
31	Pharmacokinetic Optimization of 4-Substituted Methoxybenzoyl-aryl-thiazole and 2-Aryl-4-benzoyl-imidazole for Improving Oral Bioavailability. <i>Drug Metabolism and Disposition</i> , 2011, 39, 1833-1839.	3.3	30
32	Discovery of Novel and Highly Potent Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 15946-15959.	6.4	29
33	Design, synthesis, and biological evaluation of 1-substituted -2-aryl imidazoles targeting tubulin polymerization as potential anticancer agents. <i>European Journal of Medicinal Chemistry</i> , 2019, 184, 111732.	5.5	28
34	Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 8447-8473.	6.4	28
35	Design, Synthesis, and Biological Action of 20-Hydroxyvitamin D3. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 3573-3577.	6.4	27
36	Novel CRBN-Recruiting Proteolysis-Targeting Chimeras as Degradors of Stimulator of Interferon Genes with In Vivo Anti-Inflammatory Efficacy. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 6593-6611.	6.4	26

#	ARTICLE	IF	CITATIONS
37	An Overview of HDAC Inhibitors and their Synthetic Routes. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 1005-1040.	2.1	22
38	A new steroidal 5,7-diene derivative, 3 β -hydroxyandrosta-5,7-diene-17 β -carboxylic acid, shows potent anti-proliferative activity. <i>Steroids</i> , 2010, 75, 230-239.	1.8	21
39	Nano-assembly of ursolic acid with platinum prodrug overcomes multiple deactivation pathways in platinum-resistant ovarian cancer. <i>Biomaterials Science</i> , 2021, 9, 4110-4119.	5.4	21
40	Recent Advances in the Development of PD-L1 Modulators: Degraders, Downregulators, and Covalent Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 15389-15398.	6.4	20
41	Recent Advances in c-Jun N-Terminal Kinase (JNK) Inhibitors. <i>Current Medicinal Chemistry</i> , 2021, 28, 607-627.	2.4	20
42	Discovery of Novel Histone Deacetylase 6 (HDAC6) Inhibitors with Enhanced Antitumor Immunity of Anti-PD-L1 Immunotherapy in Melanoma. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2434-2457.	6.4	20
43	Orally Bioavailable Tubulin Antagonists for Paclitaxel-Refractory Cancer. <i>Pharmaceutical Research</i> , 2012, 29, 3053-3063.	3.5	19
44	Copper-Catalyzed Selective Arylation of Nitriles with Cyclic Diaryl Iodonium Salts: Direct Access to Structurally Diversified Diarylmethane Amides with Potential Neuroprotective and Anticancer Activities. <i>Organic Letters</i> , 2020, 22, 5789-5795.	4.6	19
45	Discovery of novel CA-4 analogs as dual inhibitors of tubulin polymerization and PD-1/PD-L1 interaction for cancer treatment. <i>European Journal of Medicinal Chemistry</i> , 2021, 213, 113058.	5.5	18
46	Design, Synthesis and Biological Evaluation of Novel HIF1 α Inhibitors. <i>Anticancer Research</i> , 2015, 35, 3849-59.	1.1	17
47	Metabolism of 20-hydroxyvitamin D3 and 20,23-dihydroxyvitamin D3 by rat and human CYP24A1. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015, 149, 153-165.	2.5	16
48	Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity. <i>Bioorganic Chemistry</i> , 2021, 117, 105447.	4.1	15
49	Synthesis of <i>N</i> -Carbonyl Acridanes as Highly Potent Inhibitors of Tubulin Polymerization via One-Pot Copper-Catalyzed Dual Arylation of Nitriles with Cyclic Diphenyl Iodoniums. <i>Advanced Synthesis and Catalysis</i> , 2020, 362, 2030-2038.	4.3	14
50	Design, synthesis and biological evaluation of novel acridine and quinoline derivatives as tubulin polymerization inhibitors with anticancer activities. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 46, 116376.	3.0	14
51	Discovery of pomalidomide-based PROTACs for selective degradation of histone deacetylase 8. <i>European Journal of Medicinal Chemistry</i> , 2022, 239, 114544.	5.5	14
52	Synthesis and pharmacological evaluation of novel resorcinol biphenyl ether analogs as small molecule inhibitors of PD-1/PD-L1 with benign toxicity profiles for cancer treatment. <i>Biochemical Pharmacology</i> , 2021, 188, 114522.	4.4	13
53	Discovery of Thieno[2,3-d]pyrimidine-based KRAS G12D inhibitors as potential anticancer agents via combinatorial virtual screening. <i>European Journal of Medicinal Chemistry</i> , 2022, 233, 114243.	5.5	13
54	Discovery of novel quinazoline-based covalent inhibitors of KRAS G12C with various cysteine-targeting warheads as potential anticancer agents. <i>Bioorganic Chemistry</i> , 2021, 110, 104825.	4.1	12

#	ARTICLE	IF	CITATIONS
55	Nanocrystals Technology for Pharmaceutical Science. <i>Current Pharmaceutical Design</i> , 2018, 24, 2497-2507.	1.9	12
56	Structure Elucidation of Major Metabolites from Medroxyprogesterone Acetate by P450. <i>Chemical and Pharmaceutical Bulletin</i> , 2009, 57, 835-839.	1.3	11
57	Discovery of novel verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved Druggability for the treatment of hyperuricemia. <i>European Journal of Medicinal Chemistry</i> , 2022, 229, 114092.	5.5	11
58	Design, Synthesis, and Bioevaluation of Novel Enzyme-Triggerable Cell Penetrating Peptide-Based Dendrimers for Targeted Delivery of Camptothecin and Cancer Therapy. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 5850-5865.	6.4	9
59	Discovery of novel 3-hydroxyandrosta-5,7-Diene-17-Carboxylic acid derivatives as anti-inflammatory bowel diseases (IBD) agents. <i>European Journal of Medicinal Chemistry</i> , 2021, 220, 113468.	5.5	8
60	Effects of sidechain length and composition on the kinetic conversion and product distribution of vitamin D analogs determined by real-time NMR. <i>Dermato-Endocrinology</i> , 2013, 5, 142-149.	1.8	7
61	Discovery of ARS-1620 analogs as KRas G12C inhibitors with high in vivo antitumor activity. <i>Bioorganic Chemistry</i> , 2022, 121, 105652.	4.1	7
62	Design, synthesis and biological evaluation of benzene-fused five-membered heterocyclic compounds as tubulin polymerization inhibitors with anticancer activities. <i>Chemical Biology and Drug Design</i> , 2021, 97, 1109-1116.	3.2	6
63	Synthesis and pharmacological evaluation of a novel synthetic peptide CWHTH based on the <i>Styela clava</i> -derived natural peptide LWHTH with improved antioxidant, hepatoprotective and angiotensin converting enzyme inhibitory activities. <i>International Journal of Pharmaceutics</i> , 2021, 605, 120852.	5.2	5
64	Benzimidazole analogs as potent hypoxia inducible factor inhibitors: synthesis, biological evaluation, and profiling drug-like properties. <i>Anticancer Research</i> , 2014, 34, 3891-904.	1.1	5
65	Discovery of novel 2-aryl-4-bis-amide imidazoles (ABAI) as anti-inflammatory agents for the treatment of inflammatory bowel diseases (IBD). <i>Bioorganic Chemistry</i> , 2022, 120, 105619.	4.1	5
66	Discovery of novel 7,8-dihydropteridine-6(5H)-one-based DNA-PK inhibitors as potential anticancer agents via scaffold hopping strategy. <i>European Journal of Medicinal Chemistry</i> , 2022, 237, 114401.	5.5	5
67	Screening PEGylated polyethylenimine derivatives for safe and efficient delivery of gene materials. <i>RSC Advances</i> , 2016, 6, 106316-106326.	3.6	4
68	pH-Responsive Cross-Linked Low Molecular Weight Polyethylenimine as an Efficient Gene Vector for Delivery of Plasmid DNA Encoding Anti-VEGF-shRNA for Tumor Treatment. <i>Frontiers in Oncology</i> , 2018, 8, 354.	2.8	4
69	Novel DCPIB analogs as dual inhibitors of VRAC/TREK1 channels reduced cGAS-STING mediated interferon responses. <i>Biochemical Pharmacology</i> , 2022, 199, 114988.	4.4	4
70	Review of Design of Precursors for Sustainable Chemistry. <i>Journal of Natural Products</i> , 2017, 80, 1701-1702.	3.0	2
71	An Alkene-Forming Cascade Reaction En Route to 2,2'-Bi(glycerol). <i>Synlett</i> , 2018, 29, 1769-1772.	1.8	0